BioMarin Pharmaceutical Inc. (BMRN)

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy approved for the treatment of people with PKU SAN RAFAEL, Calif., Feb. 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for PALYNZIQ ® (pegvaliase-pqpz) to include pediatric patients 12 years of age and older with phenylketonuria (PKU).

DNB Asset Management AS increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 13.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 1,274,284 shares of the biotechnology company's stock after purchasing an additional 154,954 shares during the period. DNB Asset Management AS

BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit on Tuesday, March 10, 2026 Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 SAN RAFAEL, Calif., Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.

BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.92 per share a year ago.

Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGO Announced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify Revenues BioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26 Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

Besides Wall Street's top-and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

SAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m.

Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.

SAN RAFAEL, Calif., Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes").

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Plato Investment Management Ltd increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 59.5% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,817 shares of the biotechnology company's stock after purchasing an additional 10,005 shares during the period. Plato Investment Management Ltd's

Principal Financial Group Inc. cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 3.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 438,744 shares of the biotechnology company's stock after selling 13,638 shares during the period.